Flashcards · Module 32
🛡️ Immunosenescence & Vaccinology
4 of 4 cards published · read by the site’s author on 21 November 2026
Thymic Involution & T-Cell Repertoire Shrinkage
Needs clinical review
The Shrinking Organ:
The thymus is where T-cells mature. With age it involutes, losing epithelial cells and filling with fat.
The T-Cell Consequences:
📉 Fewer Naive T-Cells: fewer new naive CD4+ and CD8+ T-cells are made and T-cell diversity narrows, so responses to new pathogens weaken.
📈 Memory Inflation: The T-cell pool becomes crowded with exhausted, terminally differentiated effector memory cells (often occupied by lifelong chronic Cytomegalovirus [CMV] infection).
Inverted CD4:CD8 Ratio: CD8+ cells outnumber CD4+ cells (ratio <1.0), part of the immune risk profile that predicted 2-year mortality in people aged 86–94.
Sources checked (5) · 18 November 2026
- Complete fatty degeneration of thymus associates with male sex, obesity and loss of circulating naïve CD8(+) T cells in a Swedish middle-aged population (2023)
- The Role of the Thymus in the Immune Response (2019)
- Thymic Involution and Function in People With HIV and General Population Controls: A Cross-Sectional Analysis From Two Danish Cohort Studies (2026)
- MAPK-activated protein kinase 2 orchestrates memory T-cell inflation in cytomegalovirus infection (2026)
- The inverted CD4/CD8 ratio and associated parameters in 66-year-old individuals: the Swedish HEXA immune study (2013)
Note: On chest CT of middle-aged adults aged 50-64 years, 59% already had complete fatty degeneration of the thymus and 25% had predominantly fatty attenuation. (Complete fatty degeneration of thymus associates with male sex, obesity and loss of circulating naïve CD8(+) T cells in a Swedish middle-aged population (2023))
Note: Age-related thymic degeneration reduces naive T-cell export and restricts peripheral T-cell receptor diversity, impairing responses to diverse pathogens. (Prolongevity hormone FGF21 protects against immune senescence by delaying age-related thymic involution (2016))
Note: Persistent CMV infection in older adults is associated with expansion of terminally differentiated effector memory T cells (TEMRA phenotype). (The inverted CD4/CD8 ratio and associated parameters in 66-year-old individuals: the Swedish HEXA immune study (2013))
Note: In clinical profiling, IRP positivity has been defined as CMV seropositivity together with a CD4/CD8 ratio < 1 or high proportions of senescent CD8+ T cells. (NK Cells Contribute to the Immune Risk Profile in Kidney Transplant Candidates (2019))
The Geriatric Vaccine Schedule: Pneumococcal, RSV & Flu
Needs clinical review
US (ACIP) Vaccine Recommendations for Adults Aged ≥65:
| Vaccine | Indication | Recommended Regimen |
|---|---|---|
| Pneumococcal | All PCV-naïve adults ≥50 (and adults 19–49 with risk conditions) | PCV20 (Prevnar 20) or PCV21 (Capvaxive) single dose alone, OR PCV15 followed ≥1 year later by PPSV23 |
| Influenza | Annual every autumn | 🥇 High-Dose Inactivated (Fluzone High-Dose), Recombinant (Flublok), or Adjuvanted (Fluad) — superior to standard dose! |
| RSV (Respiratory Syncytial Virus) | All adults ≥75, AND adults 60–74 at increased risk for severe RSV disease | Single dose of RSV vaccine (Arexvy, Abrysvo, or mResvia) — no repeat dose currently recommended |
| Shingles | Adults ≥50 | 2 doses of Recombinant Zoster Vaccine (Shingrix) 2–6 months apart |
| COVID-19 | Annual autumn booster | Updated formulation for prevailing variants |
Sources checked (6) · 18 November 2026
- Expanded Recommendations for Use of Pneumococcal Conjugate Vaccines Among Adults Aged ≥50 Years: Recommendations of the Advisory Committee on Immunization Practices - United States, 2024 (2025)
- Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices - United States, 2024-25 Influenza Season (2024)
- Use of Respiratory Syncytial Virus Vaccines in Adults Aged ≥60 Years: Updated Recommendations of the Advisory Committee on Immunization Practices - United States, 2024 (2024)
- Use of Recombinant Zoster Vaccine in Immunocompromised Adults Aged ≥19 Years: Recommendations of the Advisory Committee on Immunization Practices - United States, 2022 (2022)
- Postlicensure Safety Surveillance of Recombinant Zoster Vaccine (Shingrix) - United States, October 2017-June 2018 (2019)
- Use of COVID-19 Vaccines for Persons Aged ≥6 Months: Recommendations of the Advisory Committee on Immunization Practices - United States, 2024-2025 (2024)
Note: If none of these three preferential vaccines is available at an opportunity for vaccine administration, any other age-appropriate influenza vaccine should be used. (Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices - United States, 2024-25 Influenza Season (2024))
Note: In older adults, the RSVpreF vaccine (Abrysvo) was associated with 18.2 extra cases of Guillain-Barré syndrome per million doses. (Updated Evidence for Covid-19, RSV, and Influenza Vaccines for 2025-2026 (2025))
Note: ACIP also recommends 2 doses of recombinant zoster vaccine for immunodeficient or immunosuppressed adults aged ≥19 years. (Use of Recombinant Zoster Vaccine in Immunocompromised Adults Aged ≥19 Years: Recommendations of the Advisory Committee on Immunization Practices - United States, 2022 (2022))
Note: Because SARS-CoV-2 circulates year-round and vaccine protection wanes, ACIP has also recommended an additional updated COVID-19 vaccine dose for adults aged ≥65 years (who accounted for 67% of COVID-19 hospitalizations during October 2023-January 2024). (Use of an Additional Updated 2023-2024 COVID-19 Vaccine Dose for Adults Aged ≥65 Years: Recommendations of the Advisory Committee on Immunization Practices - United States, 2024 (2024))
Note: Changes to the US vaccine advisory process in 2025 disrupted guidance; an independent review found the evidence still supports COVID-19, RSV and influenza vaccines for 2025–2026. (Updated Evidence for Covid-19, RSV, and Influenza Vaccines for 2025-2026 (2025))
Blunted Vaccine Responses & Adjuvants: Why high-dose flu shots are preferred
Needs clinical review
The Immunologic Problem:
Given a standard flu shot, older adults are much less likely to respond than young adults: odds ratios of 0.24 to 0.59 for seroconversion and seroprotection.
The Two High-Tech Solutions:
💥 High-Dose Vaccine (Fluzone High-Dose): Contains 4 times the antigen (60 µg vs. 15 µg of hemagglutinin per strain). In adults ≥65 it cut laboratory-confirmed flu by a further 24% compared with standard dose!
🧲 Adjuvanted Vaccine (Fluad): Contains MF59 (an oil-in-water squalene emulsion) that recruits monocytes and prolongs antigen presentation at the injection site.
Board Rule:
For adults ≥65, prefer a high-dose, recombinant or adjuvanted vaccine; if none is available, give any age-appropriate flu vaccine rather than none.
Sources checked (4) · 18 November 2026
- Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices - United States, 2024-25 Influenza Season (2024)
- Antibody response to influenza vaccination in the elderly: a quantitative review (2006)
- Efficacy of high-dose versus standard-dose influenza vaccine in older adults (2014)
- Vaccine adjuvant MF59 promotes the intranodal differentiation of antigen-loaded and activated monocyte-derived dendritic cells (2017)
Note: Across 31 antibody response studies, the adjusted odds ratio for seroconversion and seroprotection in older versus younger adults was 0.24 to 0.59, corresponding to estimated clinical vaccine efficacy of 17-53% in older adults versus 70-90% in younger adults. (Antibody response to influenza vaccination in the elderly: a quantitative review (2006))
Note: MF59 is an oil-in-water emulsion of squalene oil combined with a standard antigen dose in adjuvanted influenza vaccine for adults aged 65+ years. (An Economic Evaluation of the Adjuvanted Quadrivalent Influenza Vaccine Compared with Standard-Dose Quadrivalent Influenza Vaccine in the Spanish Older Adult Population (2022))
Reactivation Tuberculosis in Older Adults: The "Booster Phenomenon"
Needs clinical review
The Presentation Shift:
Tuberculosis in older adults mostly results from reactivation of latent infection acquired decades earlier.
Classic cavitary apical lung disease with night sweats may be completely absent!
Instead, lesions are more often in the lower lung fields, and atypical, non-specific symptoms delay diagnosis.
The PPD "Two-Step" Booster Phenomenon (The Clinical Trap!):
An older adult has latent TB, but their cell-mediated immunity is dormant.
You place a single PPD skin test → it reads 0 mm (NEGATIVE).
However, that first PPD test "wakes up" (boosts) their immune memory!
One year later, you test them again → PPD reads 14 mm (POSITIVE)!
🚨 THE MISTAKE: The clinician panics and thinks: "New hospital TB transmission!"
The Reality: It is the Booster Effect, NOT a new infection.
The Prevention: Use Two-Step PPD Testing at baseline: place a PPD; if negative, repeat a second PPD 1 to 3 weeks later to establish their true baseline!
Sources checked (8) · 18 November 2026
- Tuberculosis tracking: determining the frequency of the booster effect in patients and staff (2001)
- Challenges in treating tuberculosis in the elderly population in tertiary institute (2022)
- Progressive age-related changes in pulmonary tuberculosis images and the effect of diabetes (2000)
- What does tuberculin reactivity after bacille Calmette-Guérin vaccination tell us? (2000)
- Two-step tuberculin skin test and booster phenomenon prevalence among Brazilian medical students (2008)
- [Two-step tuberculin skin test in nurse students] (2001)
- Two-step tuberculin skin testing in HIV-infected persons in Uganda (1997)
- Two-step tuberculin skin testing of injection drug users recruited from community-based settings (1997)
Note: In a cohort comparing elderly (≥65 years) and younger patients with smear-positive pulmonary TB, night sweats were significantly less frequent in older adults (20.8% vs. 34.9%, p = 0.04). (Differences in clinical, radiological and laboratory parameters between elderly and young patients with newly diagnosed smear-positive pulmonary tuberculosis in Vietnam (2025))
Note: Atypical and nonspecific clinical manifestations of TB in older adults frequently delay diagnosis and treatment, contributing to higher morbidity and mortality. (Tuberculosis and aging: a global health problem (2001))
Note: Interferon-gamma release assays (QuantiFERON-TB Gold In-Tube and T-SPOT.TB) are also FDA-approved aids for diagnosing latent and active M. tuberculosis infection. (Updated guidelines for using Interferon Gamma Release Assays to detect Mycobacterium tuberculosis infection - United States, 2010 (2010))